Lydia Falk

Lydia Falk possesses extensive experience in regulatory affairs within the biopharmaceutical industry, having served in various leadership roles including Executive Director at Nektar Therapeutics and Head of Regulatory Affairs at Prothena Biosciences Inc. Falk has successfully led regulatory strategy for innovative products, including opioid agonists and monoclonal antibodies, and has engaged with regulatory authorities in both the US and Europe. Previous positions include Senior Director at Baxter Healthcare, where leadership encompassed global regulatory affairs for vaccines and stem cell technologies, and Assistant Vice President of Regulatory Affairs for Vaccines at Pfizer. Falk's career in regulatory affairs began at NIAID DMID and NIH, and educational credentials include a PhD in microbiology from the Uniformed Services University and a Bachelor of Science in medical technology from Douglass College, NJ. Currently, Lydia Falk is retired since May 2022.